Looking forward to ICPE in Halifax!

The DSRU team will be attending the 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) in Halifax, Canada on 23-27th August.

The wide variety of observational studies that we conduct, both at the DSRU and via a number of collaborations, will be presented in 9 research posters. Samantha Lane will help to deliver an advanced pre-conference course on methods of evidence synthesis and Dr Debabrata Roy will chair a session on Covid consequences.

The DSRU will also have a booth (#501) in the exhibition, which will showcase our capabilities as the UK’s leading unit for pharmacovigilance and pharmacoepidemiology.

If you are attending ICPE conference, do come and say hello! Members of the DSRU team would be delighted to discuss our capabilities and our research posters with you.

Discover the breadth of DSRU research and expertise at ICPE Halifax:

Thursday 24th August:
Pre-conference course: Advanced Methods I: Evidence Synthesis Methods, Living Methods, and Applied Examples in Healthcare Research

Friday 25th August
Poster 47: Utilisation patterns of the COVID-19 mRNA vaccine (Comirnaty®) from the VAC4EU active safety surveillance study in five European countries.

Poster A53: Safety monitoring of COVID-19 vaccines in multiple European countries: initial results from the COVID-19 Vaccine Monitor (CVM).

Poster 74: Safety of COVID-19 Vaccines Among People With Prior History Of SARS-Cov-2 Infection: Results From the COVID-Vaccine-Monitor Cohort Event Monitoring.

Poster 93: Rapid Production of Pharmacoepidemiology Results to Inform Regulatory Decision-making: Lessons Learned from the COVID-19 Pandemic.

Oral session moderation: COVID Consequences

Saturday 26th August
Poster 177: Utilisation and Safety of IV Bolus Formulation of Akis® for use in the Prevention and Treatment of Post-operative Pain in the UK Secondary Setting.

Poster 278: Utilisation and safety of Glycopyrronium Bromide 1mg/5ml oral solution for sialorrhoea in the paediatric population in the UK: Interim results from a non-interventional post authorisation safety study.

Lightning talk presentation: VAC4EU Study Tracking Post-Authorization Safety of mRNA-1273 in Five European Countries: How to Overcome the Methodological Challenges.

Sunday 27th August
Poster 74: Active and Passive Safety Surveillance in Children Receiving Live Attenuated Influenza Vaccine (LAIV), in England During Early Influenza Seasons from 2014/2015 to 2021/2022.

Poster 186: Appropriate Use of Observed Versus Expected Analyses for Newly Emerging Safety Concerns: The Case of Vaccine-Induced Thrombotic Thrombocytopenia Following COVID-19 Vaccination.

Poster 231: Evidence Supporting Product Withdrawals for Safety Reasons in Europe: Shift of the Trend Over Time.

Abstracts will be available on our website after the conference